论文部分内容阅读
目的 制备放射免疫导向药物用以诊断和治疗膀胱癌。 方法 通过 2 巯基直接还原标记法将放射性核素188Re(188铼 )标记抗人膀胱癌单克隆抗体BDI 1,标记产物188Re BDI 1经尾静脉注入荷人膀胱癌裸鼠体内 ,检测其在裸鼠体内的放射性分布。 结果 188Re BDI 1的标记率为30 % ,放射化学纯度为 90 % ,免疫活性分数为 5 8.6 8%。在裸鼠体内 ,肿瘤对188Re BDI 1的摄取率在2 3h达到高峰 ,以后随时间推移 ,逐步下降。 2 3h时T/NT比值 (肿瘤与正常组织的放射性计数之比 )明显增加 ,平均T/NT为 4.42 ,最大为 16 .19(肿瘤 /肌肉 ) ,随时间推移T/NT比值有所下降 ,48h时T/NT比值仍保持在高水平 10 .41(肿瘤 /肌肉 )、70h时T/NT比值 3.41(肿瘤 /肌肉 )。结论 188Re BDI 1在裸鼠体内对膀胱癌移植瘤有靶向定位作用。188Re BDI 1有可能成为膀胱癌放射免疫显像和治疗的导向药物。
Objective To prepare radioimmunoassay for the diagnosis and treatment of bladder cancer. Methods The 188Re (188 rhenium) radionuclide labeled anti-human bladder cancer monoclonal antibody BDI 1 was labeled by 2-mercapto direct reductant. The labeled product 188Re BDI 1 was injected into the tail vein of human bladder cancer nude mice. The body’s radioactive distribution. Results The labeled rate of 188Re BDI 1 was 30%, the radiochemical purity was 90%, and the immunological activity fraction was 58.6%. In nude mice, tumor uptake of 188Re BDI 1 peaked at 23 h, then decreased gradually over time. The T / NT ratio (ratio of tumor to normal radioactive counts) was significantly increased at 23 h with a mean T / NT of 4.42 and a maximum of 16.19 (tumor / muscle) with a decrease in T / NT ratio over time, At 48h, the T / NT ratio remained at a high level of 10.41 (tumor / muscle), with a T / NT ratio of 3.41 (tumor / muscle) at 70h. Conclusion 188Re BDI 1 can target the transplanted bladder cancer in nude mice. 188Re BDI 1 may become a guide for radioimmunoimaging and treatment of bladder cancer.